| In response to difficulties prescribing anti-tumour drugs after their inclusion in health insurance, and to issues arising from DRG [Diagnosis-Related Group] and disease-based payment policies that lead severely ill patients to undergo staged surgeries or be discharged and readmitted, will raise these concerns with regulators in coordination with the media. | Kreft
> Kreft: de fleste typer | Regulatorisk partnerskap
> Samarbeid med regulatoriske myndigheter | 100 000 | National | Sometimes | 114998326269 |
| We submit surveys/proposals to CFDA [China Food and Drug Administration] and CDE [Center for Drug Evaluation]. | Respiratorisk
> Pulmonal hypertensjon | Regulatorisk partnerskap
> Samarbeid med regulatoriske myndigheter | 10 000 | National | Regularly | 115007302730 |
| With respect to newly marketed medicinal products, in our capacity as the initiating body of a patient assistance programme, we gather patient perspectives and, where a therapy demonstrably meets patients' clinical needs and no clinically equivalent alternative is available in China, we advocate for its market authorisation in the country — as we have done for medicines such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy]. | Generell helse
> Folkehelse | Regulatorisk partnerskap
> Bidra til innsendinger for markedsføringstillatelse | 100 000 | National | Sometimes | 115023378250 |
| I have received an invitation from the CDE [药品审评中心 – Center for Drug Evaluation] to participate in a closed-door meeting. | Kreft
> Kreft: blod | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | 100 000 | National | Rarely | 115007439380 |
| Roundtable discussions are primarily convened by invitation from the NMPA [National Medical Products Administration]. | Kreft
> Kreft: blod | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | 100 000 | National | Rarely | 115008256034 |
| Communicating and raising concerns with the NHSA [国家医疗保障局 – National Healthcare Security Administration/China]. | Sjelden
> Fabrys sykdom | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | 1 000 | National | Regularly | 115013642356 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | Kreft
> Kreft: de fleste typer | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | 100 000 | National | Sometimes | 115033327817 |
| Participating in policy consultations and attending regulatory authority-led seminars that incorporate patient perspectives. | Sjelden
> Sjeldne sykdommer: de fleste typer | Regulatorisk partnerskap
> Delta/fasilitere møter med beslutningstakere/regulatorer | 5 000 | National | Rarely | 115063429838 |
| Submitting advocacy letters to regulatory authorities. | Sjelden
> Sjeldne sykdommer: de fleste typer | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | 1 000 | National | Regularly | 115029711188 |
| Policy advocacy and healthcare access support constitute the core areas of business. | Lever
> Hepatitt | Påvirkning av politikk og lovgivning
> Påvirk helsepolitikk og lovgivning | 100 000 | National | Regularly | 115050575369 |
| Proposals submitted to the Lianghui [两会 – the annual plenary sessions of China's National People's Congress and the Chinese People's Political Consultative Conference]. | Generell helse
> Folkehelse | Påvirkning av politikk og lovgivning
> Delta i offentlige høringer og konsultasjoner | 100 000 | National | Regularly | 115023383007 |
| Participating in policy consultations and attending regulatory authority-led seminars that incorporate patient perspectives. | Sjelden
> Sjeldne sykdommer: de fleste typer | Påvirkning av politikk og lovgivning
> Delta i offentlige høringer og konsultasjoner | 5 000 | National | Rarely | 115063429838 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | Kreft
> Kreft: de fleste typer | Prising og tilgjengelighetsadvokatur
> Gå inn for rettferdig medisinprising | 100 000 | National | Sometimes | 115030437530 |
| Patient-facing media advocacy content relating to healthcare insurance coverage. | Kreft
> Kreft: de fleste typer | Prising og tilgjengelighetsadvokatur
> Gå inn for rettferdig medisinprising | 100 000 | National | Sometimes | 115032740364 |
| We raise our voice on the issue of drug pricing. | Endokrin
> Diabetes: type 2 | Prising og tilgjengelighetsadvokatur
> Gå inn for rettferdig medisinprising | 10 000 | Regional | Rarely | 115051912364 |
| In our capacity as the initiating organization of a Patient Assistance Program (PAP) for newly approved medicines, we gather and represent patient perspectives. Where a genuine unmet clinical need exists and no clinically viable alternative is available in China, we advocate for the regulatory approval and market authorization of therapies such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy], while providing evidence on the financial burden borne by patients. | Generell helse
> Folkehelse | Prising og tilgjengelighetsadvokatur
> Adresser kostnadsbarrierer for lavinntekts- og sårbare grupper | 100 000 | National | Sometimes | 115023378250 |
| In response to difficulties prescribing anti-tumour drugs after their inclusion in the NRDL [ 国家医保药品目录 - China's National Reimbursement Drug List], and to issues arising from DRG [Diagnosis-Related Group] and disease-based payment policies that lead severely ill patients to undergo staged surgeries or be discharged and readmitted, we will raise these concerns with regulators in coordination with the media. | Kreft
> Kreft: de fleste typer | Prising og tilgjengelighetsadvokatur
> Sporing og overvåking av legemiddelpriser/legemiddelmangel | 100 000 | National | Sometimes | 114998326269 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | Kreft
> Kreft: de fleste typer | Prising og tilgjengelighetsadvokatur
> Sporing og overvåking av legemiddelpriser/legemiddelmangel | 100 000 | National | Sometimes | 115030437530 |
| We advocate for the inclusion of medications within the national medical insurance formulary, as well as for greater ease of access to treatments. | Nevrologisk
> Multippel sklerose | Prising og tilgjengelighetsadvokatur
> Arbeide for inkludering av produkt i refusjonslister/nasjonale formularer | 10 000 | National | Sometimes | 115000464773 |
| We advocate for the inclusion of medications within the national medical insurance formulary, as well as for greater ease of access to treatments. | Nevrologisk
> Multippel sklerose | Prising og tilgjengelighetsadvokatur
> Arbeide for inkludering av produkt i refusjonslister/nasjonale formularer | 10 000 | National | Sometimes | 115000464773 |
| I will advocate on issues relating to pharmaceutical pricing and the inclusion of pharmaceutical products and medical devices in the national medical insurance (NMI) reimbursement market. | Endokrin
> Diabetes: type 2 | Prising og tilgjengelighetsadvokatur
> Arbeide for inkludering av produkt i refusjonslister/nasjonale formularer | 10 000 | Regional | Rarely | 115051912364 |
| Patient-facing media advocacy content relating to healthcare insurance coverage [in China]. | Kreft
> Kreft: de fleste typer | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 100 000 | National | Sometimes | 115032740364 |
| For example, patient narratives can be disseminated through media channels to communicate patient needs around medicine accessibility. | Kreft
> Kreft: de fleste typer | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 100 000 | National | Rarely | 115037193619 |
| For example, once a medicine is included in centralised procurement, it becomes unavailable for purchase outside of hospital settings. | Reumatisk
> Lupus | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 100 000 | National | Sometimes | 115046738886 |
| Policy advocacy and healthcare access support constitute the core areas of business. | Lever
> Hepatitt | Forbedrer tilgangsveier
> Legge til rette for rettferdig tilgang til medisiner/helsetjenester | 100 000 | National | Regularly | 115050575369 |
| For example, once a medicine is included in centralised procurement, it becomes unavailable for purchase outside of hospital settings. | Reumatisk
> Lupus | Forbedrer tilgangsveier
> Adresser ulikheter i tilgang og administrasjon | 100 000 | National | Sometimes | 115046738886 |
| Patient needs and concerns should be communicated to policy-making bodies such as the National Healthcare Security Administration [国家医疗保障局 – China's national authority responsible for healthcare security and reimbursement policy]. | Hud
> Hudtilstander: de fleste typer | Evidensbasert pasientinnspill
> Bruk pasientinnsikt til å informere beslutninger | 100 000 | National | Sometimes | 115007238824 |
| With respect to newly marketed medicinal products, in our capacity as the initiating body of a patient assistance programme, we gather patient perspectives and, where a therapy demonstrably meets patients' clinical needs and no clinically equivalent alternative is available in China, we advocate for its market authorisation in the country — as we have done for medicines such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy]. | Generell helse
> Folkehelse | Evidensbasert pasientinnspill
> Bruk pasientinnsikt til å informere beslutninger | 100 000 | National | Sometimes | 115023378250 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | Kreft
> Kreft: de fleste typer | Evidensbasert pasientinnspill
> Bruk pasientinnsikt til å informere beslutninger | 100 000 | National | Sometimes | 115033327817 |
| For example, patient narratives can be disseminated through media channels to communicate patient needs around medicine accessibility. | Kreft
> Kreft: de fleste typer | Evidensbasert pasientinnspill
> Bruk pasienthistorier og fortellinger fra levd erfaring | 100 000 | National | Rarely | 115037193619 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | Kreft
> Kreft: de fleste typer | Evidensbasert pasientinnspill
> Gjennomfør undersøkelser/forskning for å generere data | 100 000 | National | Sometimes | 115030437530 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | Kreft
> Kreft: de fleste typer | Evidensbasert pasientinnspill
> Gjennomfør undersøkelser/forskning for å generere data | 100 000 | National | Sometimes | 115033327817 |
interaksjoner
handlinger & påvirkning
8 omtaler
